Publications

Olivera Finn

Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 2019;101401. doi: 10.3389/fimmu.2019.01401. PubMed PMID: 31275327; PMCID: PMC6594197.
Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: Immune modulation taking the stage. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):138-148. doi: 10.1016/j.bbcan.2017.12.002. PubMed PMID: 29391185; PMCID: PMC5955808.
Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. J Immunol. 2018 Jan 15;200(2):385-391. doi: 10.4049/jimmunol.1701302. PubMed PMID: 29311379; PMCID: PMC5763509.
Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. PubMed PMID: 29296519; PMCID: PMC5739565.
Cascio S, Faylo JL, Sciurba JC, Xue J, Ranganathan S, Lohmueller JJ, Beatty PL, Finn OJ. Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer. Oncotarget. 2017 Dec 1;8(62):105284-105298. doi: 10.18632/oncotarget.22168. PubMed PMID: 29285251; PMCID: PMC5739638.
Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018 Mar;18(3):183-194. doi: 10.1038/nri.2017.140. PubMed PMID: 29279613.
Finn OJ, Rammensee HG. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. Cold Spring Harb Perspect Biol. 2018 Nov 1;10(11): doi: 10.1101/cshperspect.a028829. PubMed PMID: 29254980; PMCID: PMC6211383.
Finn OJ. Human Tumor Antigens Yesterday, Today, and Tomorrow. Cancer Immunol Res. 2017 May;5(5):347-354. doi: 10.1158/2326-6066.CIR-17-0112. PubMed PMID: 28465452; PMCID: PMC5490447.
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346. PubMed PMID: 28373404; PMCID: PMC6681830.
Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017 Oct;17831-47. doi: 10.1016/j.pharmthera.2017.03.008. PubMed PMID: 28322974; PMCID: PMC5600680.
Cascio S, Finn OJ. Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis. Biomolecules. 2016 Oct 13;6(4): doi: 10.3390/biom6040039. PubMed PMID: 27754373; PMCID: PMC5197949.
Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer Immunol Res. 2016 Oct;4(10):881-892. doi: 10.1158/2326-6066.CIR-15-0189. PubMed PMID: 27604597; PMCID: PMC5331878.
Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep. 2016 Aug 22;631740. doi: 10.1038/srep31740. PubMed PMID: 27545199; PMCID: PMC4992835.
Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol Immunother. 2016 Jul;65(7):771-8. doi: 10.1007/s00262-016-1838-1. PubMed PMID: 27106024.
Finn OJ, Beatty PL. Cancer immunoprevention. Curr Opin Immunol. 2016 Apr;3952-8. doi: 10.1016/j.coi.2016.01.002. PubMed PMID: 26799207; PMCID: PMC4805487.
Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A. Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study. Dis Markers. 2015;2015179689. doi: 10.1155/2015/179689. PubMed PMID: 26693201; PMCID: PMC4676998.
Finn OJ, Khleif SN, Herberman RB. The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them. Cancer Prev Res (Phila). 2015 Nov;8(11):1011-6. doi: 10.1158/1940-6207.CAPR-15-0234. PubMed PMID: 26353948; PMCID: PMC4633304.
Cascio S, Finn OJ. Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis. Cancers (Basel). 2015 Feb 10;7(1):342-52. doi: 10.3390/cancers7010342. PubMed PMID: 25675408; PMCID: PMC4381262.
Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res. 2014 Aug;2(8):708-13. doi: 10.1158/2326-6066.CIR-14-0110. PubMed PMID: 25092812; PMCID: PMC4163937.

<< Investigators Search

Top